Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).

Literature DB >> 8103994

Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).

J Staedt¹, G Stoppe, A Kögler, D Munz, H Riemann, D Emrich, E Rüther.

Abstract

Periodic movements in sleep (PMS) can cause severe sleep disturbances. We investigated the central dopamine D2 receptor density in patients with PMS with 123I-IBZM and single photon emission tomography (SPET). In PMS there was a lower 123I-IBZM binding in the basal ganglia compared to the control group. The results indicate a loss of central D2 receptors in PMS.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1993 PMID： 8103994 DOI： 10.1007/bf01244940

Source DB: PubMed Journal: J Neural Transm Gen Sect

11 in total

1. Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen.

Authors: V L Dawson; T M Dawson; F M Filloux; J K Wamsley
Journal: Life Sci Date: 1988 Impact factor: 5.037

2. Cerebral decortication reverses the effect of amphetamine on striatal D2 dopamine binding site density.

Authors: H A Robertson
Journal: Neurosci Lett Date: 1986-12-23 Impact factor: 3.046

3. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome.

Authors: A S Walters; W A Hening; N Kavey; S Chokroverty; S Gidro-Frank
Journal: Ann Neurol Date: 1988-09 Impact factor: 10.422

4. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.

Authors: T Brücke; I Podreka; P Angelberger; S Wenger; A Topitz; B Küfferle; C Müller; L Deecke
Journal: J Cereb Blood Flow Metab Date: 1991-03 Impact factor: 6.200

5. Treatment of restless legs syndrome with levodopa plus benserazide.

Authors: S Akpinar
Journal: Arch Neurol Date: 1982-11

6. Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa.

Authors: J Montplaisir; R Godbout; G Poirier; M A Bédard
Journal: Clin Neuropharmacol Date: 1986 Impact factor: 1.592

7. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans.

Authors: D C Costa; N P Verhoeff; I D Cullum; P J Ell; G M Syed; J Barrett; E Palazidou; B Toone; E Van Royen; M Bobeldijk
Journal: Eur J Nucl Med Date: 1990

8. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.

Authors: C Brodeur; J Montplaisir; R Godbout; R Marinier
Journal: Neurology Date: 1988-12 Impact factor: 9.910

9. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study.

Authors: J Montplaisir; R Godbout; D Boghen; J DeChamplain; S N Young; G Lapierre
Journal: Neurology Date: 1985-01 Impact factor: 9.910

10. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.

Authors: K Tatsch; J Schwarz; W H Oertel; C M Kirsch
Journal: Nucl Med Commun Date: 1991-08 Impact factor: 1.690

22 in total

Review 1. Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors: Svenja Happe; Claudia Trenkwalder
Journal: CNS Drugs Date: 2004 Impact factor: 5.749

Review 2. [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors: S Happe; W Paulus
Journal: Nervenarzt Date: 2006-06 Impact factor: 1.214

3. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Authors: J Staedt; F Wassmuth; U Ziemann; G Hajak; E Rüther; G Stoppe
Journal: J Neural Transm (Vienna) Date: 1997 Impact factor: 3.575

Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).

1. Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen.

2. Cerebral decortication reverses the effect of amphetamine on striatal D2 dopamine binding site density.

3. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome.

4. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.

5. Treatment of restless legs syndrome with levodopa plus benserazide.

6. Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa.

7. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans.

8. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.

9. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study.

10. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.

Review 1. Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Review 2. [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

3. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

4. Longitudinal relationships of periodic limb movements during sleep and incident atrial fibrillation.

5. Periodic leg movements in sleep in elderly patients with Parkinsonism and Alzheimer's disease.

6. Apomorphine in idiopathic restless legs syndrome: an exploratory study.

Review 7. Imaging brain functional and metabolic changes in restless legs syndrome.

Review 8. Sleep-related non epileptic motor disorders.

9. Ropinirole in restless legs syndrome and periodic limb movement disorder.

10. Increased synaptic dopamine in the putamen in restless legs syndrome.